The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1418
Lubiprostone (Amitiza) for Opioid-Induced Constipation
The full article is available to subscribers Subscriber Login   

The FDA has approved use of lubiprostone (Amitiza) for treatment of opioid-induced constipation in adults with chronic non-cancer pain. The drug was previously approved for chronic idiopathic constipation and irritable bowel syndrome with constipation.1,2

OPIOID-INDUCED CONSTIPATION — Patients develop tolerance to the analgesic and CNS-depressant effects of opioids, but not to constipation, which can be dose-limiting or cause discontinuation of therapy. It is usually treated with laxatives and stool softeners, which have limited efficacy.3 Methylnaltrexone (Relistor), a mu-opioid receptor antagonist that must be given subcutaneously, is FDA-approved for treatment of opioid-induced constipation in patients with advanced illness receiving palliative care; it apparently does not cross the blood-brain barrier and therefore does ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: Lubiprostone (Amitiza) for Opioid-Induced Constipation
Article code: 1418c
 Electronic, downloadable article - $25